KORU Medical Systems to Report Third Quarter 2024 Financial Results on November 13, 2024

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

MAHWAH, N.J.–(BUSINESS WIRE)–KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company will report third quarter 2024 financial results on Wednesday, November 13, 2024. KORU Medical’s management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update.


Conference Call and Webcast Details

The conference call can be accessed by dialing (877)-407-0784 for participants in the U.S. or Canada and (201)-689-8560 for international callers. A live and archived webcast of the event can be accessed via the IR Calendar on the News/Events page of the Investors section of KORU Medical’s website at www.korumedical.com. The archived webcast will be available for six months.

About KORU Medical Systems

KORU Medical Systems develops, manufactures, and commercializes innovative and patient-centric large volume subcutaneous infusion solutions that improve quality of life for patients around the world. The FREEDOM Syringe Infusion System (the “Freedom System”) currently includes the FREEDOM60® and FreedomEdge® Syringe Infusion Drivers, Precision Flow Rate Tubing™ and HIgH-Flo Subcutaneous Safety Needle Sets™. The Freedom System, which received its first FDA clearance in 1994, is used for self-administration in the home by the patient and/or delivery in an ambulatory infusion center by a healthcare professional. Through its Novel Therapies business, KORU Medical provides products for use by biopharmaceutical companies in feasibility/clinical trials during the drug development process and, as needed, is capable of customizing the Freedom System for clinical and commercial use across multiple drug categories. For more information, please visit www.korumedical.com.

Contacts

Investor Contact:
Greg Chodaczek

347-620-7010

investor@korumedical.com

Staff

Recent Posts

FendX Announces Share Issuance Pursuant to IP License Agreement

Oakville, Ontario--(Newsfile Corp. - May 5, 2025) - FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF)…

3 hours ago

The Lens Magazine Features Joe Kiani, Willow Laboratories Founder and Nutu Visionary, on Cover of Latest Issue Following LSI USA ‘25 Keynote

DANA POINT, Calif.--(BUSINESS WIRE)--The Lens, LSI’s executive-focused medtech magazine, proudly unveils Volume 2, Edition 3,…

5 hours ago

eMed Announces Collaboration with Aon to Provide a Digital GLP-1 Benefit Program for Aon colleagues

Partnership provides virtual clinical support with data driven measurement to improve adherence for obesity management MIAMI, May 5, 2025 /PRNewswire/ -- eMed®,…

5 hours ago

First Partner Jennifer Siebel Newsom Unveils Tech/Life Balance Guide in Conversation with Jonathan Haidt at Milken Institute Global Conference

In a featured conversation with social psychologist and author Jonathan Haidt, First Partner Jennifer Siebel…

5 hours ago

Abu Dhabi’s economic delegation to Japan explores new avenues to strengthen partnerships

ABU DHABI, UAE, May 5, 2025 /PRNewswire/ -- As part of Abu Dhabi's ongoing efforts…

5 hours ago